10 June 2025
EMA/188363/2025 Rev. 1*
Committee for Medicinal Products for Human Use (CHMP)

Emtricitabine/Rilpivirine/Tenofovir Disoproxil film-coated tablets 200 mg/25 mg/245 mg product-specific bioequivalence guidance

Draft agreed by Pharmacokinetics Working Party	October 2016
Adopted by CHMP for release for consultation	15 December 2016
Start of public consultation	22 December 2016
End of consultation (deadline for comments)	31 March 2017
Agreed by Pharmacokinetics Working Party	April 2017
Adopted by CHMP	22 June 2017
Date of coming into effect	1 January 2018
Draft revision agreed by Methodology Working Party (MWP)	3 April 2025
Adopted by CHMP	10 June 2025
Date of coming into effec	1 January 2026

* This revision relates to the addition of the salt form

Keywords	***Bioequivalence, generics, emtricitabine/rilpivirine/tenofovir disoproxil***

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Emtricitabine/rilpivirine/tenofovir disoproxil film-coated tablets 200 mg/25 mg/245 mg product-specific bioequivalence guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (MWP)*

BCS Classification**	**BCS Class:** ☐ **I** ☐ **III** ☒ **Neither of the two** **Background:** Emtricitabine may be considered a high solubility compound. Rilpivirine hydrochloride may be considered a low solubility compound. Tenofovir disoproxil fumarate may be considered a high solubility compound.
Bioequivalence study design *in case a BCS biowaiver is not feasible or applied*	**single dose** **cross-over**
	healthy volunteers
	☐ **fasting** ☒ **fed** ☐ **both** ☐ **either fasting or fed**

	Strength: 200 mg/25 mg/245 mg for emtricitabine/rilpivirine/tenofovir disoproxil. **Background:** 200 mg/25 mg/245 mg is the only available combination strength.
	Number of studies: one single dose study
Analyte	☒ **parent** ☒ **metabolite** ☐ **both** For emtricitabine and rilpivirine the parent, for tenofovir disoproxil the metabolite (as tenofovir).
	☒ **plasma/serum** ☐ **blood** ☐ **urine**
	Enantioselective analytical method: ☐ **yes** ☒ **no**
Bioequivalence assessment	**Main pharmacokinetic variables:** AUC_{0-t} and C_{max} for emtricitabine and tenofovir**.** AUC_{0-72} and C_{max} for rilpivirine.
	90% confidence interval: 80.00–125.00%

* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C_{max}. If high intra-individual variability (CV_{intra} > 30%) is expected, the applicants might follow respective guideline recommendations.

** This tentative BCS classification of the drug substance serves to define whether *in vivo* studies seem to be mandatory (BCS class II and IV) or, on the contrary (BCS Class I and III), the Applicant may choose between two options: *in vivo* approach or *in vitro* approach based on a BCS biowaiver. In this latter case, the BCS classification of the drug substance should be confirmed by the Applicant at the time of submission based on available data (solubility experiments, literature, etc.). However, a BCS-based biowaiver might not be feasible due to product specific characteristics despite the drug substance being BCS class I or III (e.g. *in vitro* dissolution being less than 85% within 15 min (BCS class III) or 30 min (BCS class I) either for test or reference, or unacceptable differences in the excipient composition).